Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.40)
# 295
Out of 5,173 analysts
119
Total ratings
55.05%
Success rate
17.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Initiates: Buy | $26 | $7.14 | +264.15% | 1 | Mar 20, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $49.00 | +18.37% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $250.08 | +13.56% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $54.78 | +56.99% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $30.01 | +49.95% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $4.78 | +46.44% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $11.49 | +74.06% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $20.27 | +156.54% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $2.40 | +150.00% | 4 | Dec 12, 2025 | |
| PHVS Pharvaris | Maintains: Buy | $32 → $39 | $25.70 | +51.75% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $43 | $26.00 | +65.38% | 8 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $17.71 | +7.28% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.54 | +441.52% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $15.92 | +496.73% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $70.79 | +29.96% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $31.72 | +234.17% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $7.03 | +42.35% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.11 | +6.79% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $451.24 | +21.00% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $17.87 | +179.80% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $25.17 | +118.51% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.58 | +402.79% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.19 | +51.92% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.42 | +4.02% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $46.88 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.52 | +191.41% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.88 | +467.01% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.44 | +1,088.52% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $306.66 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $4.54 | +516.74% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $11.62 | +72.12% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $31.90 | +285.58% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $24.02 | +124.81% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.15 | +5,117.39% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.11 | - | 3 | Jun 26, 2017 |
Solid Biosciences
Mar 20, 2026
Initiates: Buy
Price Target: $26
Current: $7.14
Upside: +264.15%
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $49.00
Upside: +18.37%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $250.08
Upside: +13.56%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $54.78
Upside: +56.99%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $30.01
Upside: +49.95%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $4.78
Upside: +46.44%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $11.49
Upside: +74.06%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $20.27
Upside: +156.54%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $2.40
Upside: +150.00%
Pharvaris
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $25.70
Upside: +51.75%
Nov 18, 2025
Maintains: Buy
Price Target: $28 → $43
Current: $26.00
Upside: +65.38%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $17.71
Upside: +7.28%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $5.54
Upside: +441.52%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $15.92
Upside: +496.73%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $70.79
Upside: +29.96%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $31.72
Upside: +234.17%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $7.03
Upside: +42.35%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.11
Upside: +6.79%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $451.24
Upside: +21.00%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $17.87
Upside: +179.80%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $25.17
Upside: +118.51%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.58
Upside: +402.79%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.19
Upside: +51.92%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.42
Upside: +4.02%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $46.88
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $6.52
Upside: +191.41%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.88
Upside: +467.01%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.44
Upside: +1,088.52%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $306.66
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $4.54
Upside: +516.74%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $11.62
Upside: +72.12%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $31.90
Upside: +285.58%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $24.02
Upside: +124.81%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.15
Upside: +5,117.39%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $28.11
Upside: -